Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...
VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- , Inc. (“Jade”), a biotechnology company ...
New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...
Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for ...
The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry ...
Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results